0.00
+0(+0.00%)
Currency In USD
| Previous Close | 0 |
| Open | 0 |
| Day High | 0 |
| Day Low | 0 |
| 52-Week High | 1.03 |
| 52-Week Low | 0 |
| Volume | 568,619 |
| Average Volume | 2.91M |
| Market Cap | 593,177 |
| PE | 0 |
| EPS | -0.91 |
| Moving Average 50 Days | 0.01 |
| Moving Average 200 Days | 0.08 |
| Change | 0 |
If you invested $1000 in Ocean Biomedical, Inc. (OCEA) since IPO date, it would be worth $0.1 as of October 20, 2025 at a share price of $0.001. Whereas If you bought $1000 worth of Ocean Biomedical, Inc. (OCEA) shares 3 years ago, it would be worth $0.1 as of October 20, 2025 at a share price of $0.001.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocean Biomedical Expands into Energy and Digital Asset Sectors to Accelerate Growth and Shareholder Value
GlobeNewswire Inc.
Apr 22, 2025 12:00 PM GMT
Strategic diversification into power infrastructure and cryptocurrencies supports long-term biopharma innovation PROVIDENCE, R.I., April 22, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on pion
Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China
GlobeNewswire Inc.
Mar 28, 2025 12:30 PM GMT
PROVIDENCE, R.I., March 28, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company dedicated to advancing innovative treatments for cancer, infectious diseases, and fibrosis, today announced that the China Natio
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
GlobeNewswire Inc.
Feb 10, 2025 1:00 PM GMT
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly published research findings demonstrating the ability of